| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/06/2001 | CA2410516A1 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 12/06/2001 | CA2410514A1 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | CA2410485A1 Thrombospondin-1 type 1 repeat polypeptides |
| 12/06/2001 | CA2410470A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2410453A1 Neuroprotective peptides |
| 12/06/2001 | CA2410265A1 Lyophilizable and enhanced compacted nucleic acids |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2410033A1 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | CA2410015A1 Methods of transducing neural cells using lentivirus vectors |
| 12/06/2001 | CA2409932A1 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | CA2409921A1 Cosmetic composition comprising human serum albumin obtained from transgenic non-human animals |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2409267A1 Use of interleukin-4 antagonists and compositions thereof |
| 12/06/2001 | CA2409188A1 Polyubiquitin based hydrogel and uses thereof |
| 12/06/2001 | CA2408103A1 Tumor activated prodrug compounds and methods of making and using the same |
| 12/06/2001 | CA2380367A1 Compositions for providing zinc through oral administration |
| 12/05/2001 | EP1160323A1 5T4 tumour-associated antigen for use in tumour immunotherapy |
| 12/05/2001 | EP1160322A2 Human melanocyte stimulating hormone receptors |
| 12/05/2001 | EP1160321A1 Kidney Injury Novel Gene-1: Isolation and therapeutic applications |
| 12/05/2001 | EP1160320A1 Use of hTAFII80 and isoforms thereof for inducing apoptosis |
| 12/05/2001 | EP1160318A2 Medicament for treatment of Duchenne muscular dystrophy |
| 12/05/2001 | EP1160256A2 Monoclonal antibody specific for beta-A4 peptide |
| 12/05/2001 | EP1160254A1 Human vanilloid receptor-like proteins |
| 12/05/2001 | EP1160253A1 A gene encoding a polypeptide having pre-B cell growth-supporting ability |
| 12/05/2001 | EP1160236A2 Production of mixed acid anhydride and amine compound |
| 12/05/2001 | EP1159975A2 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159974A1 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159964A2 Compositions and methods for stimulating gastrointestinal motility |
| 12/05/2001 | EP1159958A1 Vaseline-based nasal ointment |
| 12/05/2001 | EP1159951A1 Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
| 12/05/2001 | EP1159457A1 T cell receptor vbeta beta-jbeta) sequence and methods for its detection |
| 12/05/2001 | EP1159455A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 12/05/2001 | EP1159438A1 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 12/05/2001 | EP1159431A2 Human kallikrein-like genes |
| 12/05/2001 | EP1159430A1 Histidin protein-phosphatase |
| 12/05/2001 | EP1159427A1 Gp120 mutants and biological applications |
| 12/05/2001 | EP1159423A2 Uses of transgenic animals containing a type x collagen mutant |
| 12/05/2001 | EP1159422A1 Compositions and methods for the treatment of tumors |
| 12/05/2001 | EP1159420A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 12/05/2001 | EP1159419A1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159413A2 Secreted proteins and uses thereof |
| 12/05/2001 | EP1159412A2 Composition, methods and reagents for the synthesis of a soluble form of human phex |
| 12/05/2001 | EP1159409A1 Introducing a biological material into a patient |
| 12/05/2001 | EP1159408A2 Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof |
| 12/05/2001 | EP1159328A1 Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159299A1 Mammalian cytokines; related reagents and methods |
| 12/05/2001 | EP1159296A1 METHOD FOR PRODUCING CYCLO-(Asp-DPhe-NMeVal-Arg-Gly) |
| 12/05/2001 | EP1159295A1 Method of purifying whey of lactic acid fermentation by electrodialysis |
| 12/05/2001 | EP1159292A2 Compounds having growth hormone releasing activity |
| 12/05/2001 | EP1159291A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 12/05/2001 | EP1159288A1 Alpha-conotoxin peptides |
| 12/05/2001 | EP1159287A1 50 human secreted proteins |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159284A1 33 human secreted proteins |
| 12/05/2001 | EP1159008A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors |
| 12/05/2001 | EP1159007A1 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| 12/05/2001 | EP1159006A2 Water-soluble compositions of bioactive lipophilic compounds |
| 12/05/2001 | EP1159000A2 Preparation for the treatment of pigmentation disorders |
| 12/05/2001 | EP1158999A2 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 12/05/2001 | EP1158998A1 Cardiac muscle function and manipulation |
| 12/05/2001 | EP1158997A2 Method of promoting myocyte proliferation and myocardial tissue repair |
| 12/05/2001 | EP1158996A1 Novel amide derivatives as growth hormone secretagogues |
| 12/05/2001 | EP1158993A1 Bacterial membrane fractions with adjuvant effect |
| 12/05/2001 | EP1158991A1 Treatment of asthma |
| 12/05/2001 | EP1158959A1 Compositions and methods for improved delivery of hydrophobic therapeutic agents |
| 12/05/2001 | EP1158856A1 Human fas |
| 12/05/2001 | EP1158854A1 Organ transplant solutions containing conjugates of soluble peptidic compounds withmembrane-binding agents |
| 12/05/2001 | EP0970195A4 Fatty-acid amide hydrolase |
| 12/05/2001 | EP0939765B1 Glycoconjugates of modified camptothecin derivatives (a- or b-ring linkage) |
| 12/05/2001 | EP0914324B1 Specific inhibitors of dna methyltransferase enzyme |
| 12/05/2001 | EP0912898B1 Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg |
| 12/05/2001 | EP0912197B1 Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers |
| 12/05/2001 | EP0873363A4 Novel high affinity human antibodies to tumor antigens |
| 12/05/2001 | EP0859596B1 Gel formulations containing growth factors |
| 12/05/2001 | EP0845003B1 Novel opioid peptides |
| 12/05/2001 | EP0835263B1 Somatostatin peptides |
| 12/05/2001 | EP0814841B1 Hcg liquid formulations |
| 12/05/2001 | EP0783522B1 PEPTIDES FROM THE hPTH SEQUENCE (1-37) |
| 12/05/2001 | EP0769056B1 NON-SPLICING VARIANTS OF gp350/220 |
| 12/05/2001 | EP0763114B1 Hepatitis g virus and molecular cloning thereof |
| 12/05/2001 | EP0751954B1 Anti-inflammatory composition and method with des-tyr dynorphin and analogues |
| 12/05/2001 | EP0720484B1 Plant material for controlling immune responses in mammals and method for producing the material |
| 12/05/2001 | EP0692972B1 Method for delivering beneficial compositions to hair follicles |
| 12/05/2001 | EP0669912B1 N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists |
| 12/05/2001 | EP0445255B2 USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUMOUR AGENTS AND/OR NSAIDs FOR TREATING CANCER |
| 12/05/2001 | CN1325450A Adenovirus-mediated gene therapy |
| 12/05/2001 | CN1325447A Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
| 12/05/2001 | CN1325443A Glycosylated proteins having reduced allergenicity |
| 12/05/2001 | CN1325442A Endothelial cell proliferation inhibitors derived from human prothrombin |
| 12/05/2001 | CN1325441A Modified exosomes and uses |
| 12/05/2001 | CN1325408A Compounds with growth hormone releasing propenties |
| 12/05/2001 | CN1325407A Platelet-derived growth factor D, DNA coding therefor and uses thereof |
| 12/05/2001 | CN1325406A Crystalline forms of EtO2C-ch2-(r) Cgl-Aze-Pab-oh |
| 12/05/2001 | CN1325404A Low allergenic proteinvariants |
| 12/05/2001 | CN1325376A Novel compounds and medicinal use thereof |